$CAPR
CAPRICOR THERAPEUTICS, INC.

2024 Q3 Form 10-Q Financial Statement

#000155837024011638 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $2.262M $3.971M
YoY Change -63.44% 1.38%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.464M $3.058M
YoY Change 14.69% 7.39%
% of Gross Profit
Research & Development $11.80M $12.50M
YoY Change 18.0% 42.05%
% of Gross Profit
Depreciation & Amortization $361.2K $356.9K
YoY Change 30.63% 40.14%
% of Gross Profit
Operating Expenses $15.27M $15.56M
YoY Change 17.02% 33.42%
Operating Profit -$13.01M -$11.59M
YoY Change 89.52% 49.62%
Interest Expense $453.2K $591.4K
YoY Change -5.59% 55.36%
% of Operating Profit
Other Income/Expense, Net $453.2K $591.4K
YoY Change -4.4% 55.36%
Pretax Income -$12.56M -$11.00M
YoY Change 96.51% 49.32%
Income Tax
% Of Pretax Income
Net Earnings -$12.56M -$11.00M
YoY Change 96.49% 49.32%
Net Earnings / Revenue -555.2% -276.97%
Basic Earnings Per Share -$0.38 -$0.35
Diluted Earnings Per Share -$0.38 -$0.35
COMMON SHARES
Basic Shares Outstanding 32.54M 31.81M
Diluted Shares Outstanding 33.09M 31.84M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $85.03M $29.46M
YoY Change 198.14% -22.04%
Cash & Equivalents $68.38M $10.69M
Short-Term Investments $16.65M $18.77M
Other Short-Term Assets $385.1K $837.2K
YoY Change -16.29% 43.4%
Inventory
Prepaid Expenses $317.1K
Receivables $409.7K $370.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $85.82M $30.67M
YoY Change 190.66% -21.21%
LONG-TERM ASSETS
Property, Plant & Equipment $5.315M $5.618M
YoY Change 3.42% 17.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $319.3K $319.6K
YoY Change 18.24% 19.16%
Total Long-Term Assets $7.128M $7.608M
YoY Change -6.51% 7.36%
TOTAL ASSETS
Total Short-Term Assets $85.82M $30.67M
Total Long-Term Assets $7.128M $7.608M
Total Assets $92.95M $38.28M
YoY Change 150.19% -16.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.531M $6.170M
YoY Change -3.81% 20.18%
Accrued Expenses $813.6K $792.7K
YoY Change 11.46% 12.05%
Deferred Revenue $13.13M $15.39M
YoY Change -48.32% -47.49%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.48M $22.35M
YoY Change -37.81% -36.41%
LONG-TERM LIABILITIES
Long-Term Debt $3.376M $3.376M
YoY Change -0.11% 0.0%
Other Long-Term Liabilities $834.9K $1.044M
YoY Change -68.38% -78.02%
Total Long-Term Liabilities $4.211M $4.420M
YoY Change -29.97% -45.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.48M $22.35M
Total Long-Term Liabilities $4.211M $4.420M
Total Liabilities $24.69M $26.78M
YoY Change -36.6% -38.14%
SHAREHOLDERS EQUITY
Retained Earnings -$192.7M -$180.2M
YoY Change 21.5% 18.36%
Common Stock $260.9M $191.5M
YoY Change 66.48% 23.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.26M $11.50M
YoY Change
Total Liabilities & Shareholders Equity $92.95M $38.28M
YoY Change 150.19% -16.81%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$12.56M -$11.00M
YoY Change 96.49% 49.32%
Depreciation, Depletion And Amortization $361.2K $356.9K
YoY Change 30.63% 40.14%
Cash From Operating Activities -$11.64M -$12.29M
YoY Change 32.45% 30.48%
INVESTING ACTIVITIES
Capital Expenditures $59.03K $80.90K
YoY Change -90.63% -65.34%
Acquisitions
YoY Change
Other Investing Activities $2.064M $14.78M
YoY Change -75.29% 120.71%
Cash From Investing Activities $2.005M $14.70M
YoY Change -74.03% 127.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 67.33M 2.067M
YoY Change 30503.12% -5.53%
NET CHANGE
Cash From Operating Activities -11.64M -12.29M
Cash From Investing Activities 2.005M 14.70M
Cash From Financing Activities 67.33M 2.067M
Net Change In Cash 57.69M 4.474M
YoY Change -6886.95% -682.22%
FREE CASH FLOW
Cash From Operating Activities -$11.64M -$12.29M
Capital Expenditures $59.03K $80.90K
Free Cash Flow -$11.70M -$12.37M
YoY Change 24.22% 28.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001133869
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31983927
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31148320
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31148320
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31983927
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y5M7D
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34058
dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0363465
dei Entity Address Address Line1
EntityAddressAddressLine1
10865 Road to the Cure, Suite 150, San Diego
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
727-1755
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CAPR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32538930
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10688363
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14694857
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
18773667
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
24792846
CY2024Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
369975
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
10371993
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
837218
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
995776
CY2024Q2 us-gaap Assets Current
AssetsCurrent
30669223
CY2023Q4 us-gaap Assets Current
AssetsCurrent
50855472
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5617523
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5560641
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1671149
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2050042
CY2024Q2 us-gaap Other Assets
OtherAssets
319558
CY2023Q4 us-gaap Other Assets
OtherAssets
268172
CY2024Q2 us-gaap Assets
Assets
38277453
CY2023Q4 us-gaap Assets
Assets
58734327
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6169934
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6250241
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
792694
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
749112
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
15392151
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
24270465
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22354779
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31269818
CY2024Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1044109
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1486783
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4420368
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4863042
CY2024Q2 us-gaap Liabilities
Liabilities
26775147
CY2023Q4 us-gaap Liabilities
Liabilities
36132860
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31983927
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
31984
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
31148
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
191476543
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
181701859
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
154987
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
235813
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180161208
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159367353
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
11502306
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
22601467
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38277453
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58734327
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3971438
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3917467
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8878315
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6904163
CY2024Q2 us-gaap Revenues
Revenues
3971438
CY2023Q2 us-gaap Revenues
Revenues
3917467
us-gaap Revenues
Revenues
8878315
us-gaap Revenues
Revenues
6904163
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12504769
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8817389
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23605782
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16478908
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3057888
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2847337
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7129654
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6357222
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
15562657
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
11664726
us-gaap Operating Expenses
OperatingExpenses
30735436
us-gaap Operating Expenses
OperatingExpenses
22836130
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11591219
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7747259
us-gaap Operating Income Loss
OperatingIncomeLoss
-21857121
us-gaap Operating Income Loss
OperatingIncomeLoss
-15931967
CY2024Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
591437
CY2023Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
380680
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1063266
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
797122
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
591437
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
380680
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1063266
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
797122
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10999782
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7366579
us-gaap Net Income Loss
NetIncomeLoss
-20793855
us-gaap Net Income Loss
NetIncomeLoss
-15134845
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-152714
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84707
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-80826
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
74449
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11152496
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7281872
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20874681
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15060396
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31841964
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31841964
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25335342
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25335342
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31598296
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31598296
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25291591
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25291591
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
22601467
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2290244
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3265412
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
71888
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-9794073
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
18434938
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1985849
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2152793
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81222
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-152714
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10999782
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
11502306
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2194784
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3895
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10258
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7768266
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6206249
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2130395
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1618712
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57679
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84707
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7366579
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2731163
us-gaap Profit Loss
ProfitLoss
-20793855
us-gaap Profit Loss
ProfitLoss
-15134845
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
688341
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
484803
us-gaap Share Based Compensation
ShareBasedCompensation
5418205
us-gaap Share Based Compensation
ShareBasedCompensation
3813496
capr Noncash Lease Expenses
NoncashLeaseExpenses
-20199
capr Noncash Lease Expenses
NoncashLeaseExpenses
-12904
capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
-10002018
capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-158558
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-336057
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
51386
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-80307
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
209892
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8878314
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
5095837
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13556939
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5207664
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
49283647
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
52863856
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
55222000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
56800000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
668928
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
483563
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
76295
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
202995
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5193130
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3249586
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4276093
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2130395
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
81222
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
61574
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4357315
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2191969
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4006494
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
233891
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14694857
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9603242
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10688363
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9837133
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain reclassification of prior period amounts has been made to conform to the current year presentation.</p>
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
29500000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
39500000
CY2020Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191199
CY2023 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191463
CY2024Q2 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
366551
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p>
CY2024Q2 us-gaap Depreciation
Depreciation
356935
CY2023Q2 us-gaap Depreciation
Depreciation
254702
us-gaap Depreciation
Depreciation
688341
us-gaap Depreciation
Depreciation
484803
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8496179
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7766696
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2878656
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2206055
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5617523
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5560641
capr Grant Income
GrantIncome
0
CY2023Q2 capr Grant Income
GrantIncome
0
capr Grant Income
GrantIncome
0
CY2024Q2 capr Grant Income
GrantIncome
0
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12500000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8800000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23600000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16500000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11200000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7300000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20900000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15100000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-152714
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84707
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-80826
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
74449
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15631881
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15631881
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7784934
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7784934
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31983927
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
CY2023Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
5.61
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
CY2024Q2 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
5.61
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
capr Share Based Compensation Number Of Plans
ShareBasedCompensationNumberOfPlans
5
CY2021Q2 capr Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Annual Increase In Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInNumberOfSharesAuthorized
0.05
capr Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock
MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock
100000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.18
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2152793
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1618712
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5418205
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3813496
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
19200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2024Q2 capr Number Of Financial Institutions
NumberOfFinancialInstitutions
3
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
29200000
CY2024Q2 us-gaap Short Term Lease Payments
ShortTermLeasePayments
380357
CY2023Q2 us-gaap Short Term Lease Payments
ShortTermLeasePayments
23607
us-gaap Short Term Lease Payments
ShortTermLeasePayments
764714
us-gaap Short Term Lease Payments
ShortTermLeasePayments
47214
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
317097
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
447776
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
914220
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
634889
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1996885
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
160082
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1836803
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
792694
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1044109
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1836803
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.074
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1700000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1800000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
210357
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
192606
us-gaap Operating Lease Cost
OperatingLeaseCost
420714
us-gaap Operating Lease Cost
OperatingLeaseCost
385212
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
229197
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
199058
us-gaap Operating Lease Payments
OperatingLeasePayments
455822
us-gaap Operating Lease Payments
OperatingLeasePayments
398116
capr Severance Package To Be Paid For Period Of Base Salary
SeverancePackageToBePaidForPeriodOfBaseSalary
P6M
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-011638-index-headers.html Edgar Link pending
0001558370-24-011638-index.html Edgar Link pending
0001558370-24-011638.txt Edgar Link pending
0001558370-24-011638-xbrl.zip Edgar Link pending
capr-20240630.xsd Edgar Link pending
capr-20240630x10q.htm Edgar Link pending
capr-20240630xex31d1.htm Edgar Link pending
capr-20240630xex31d2.htm Edgar Link pending
capr-20240630xex32d1.htm Edgar Link pending
capr-20240630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
capr-20240630_cal.xml Edgar Link unprocessable
capr-20240630_def.xml Edgar Link unprocessable
capr-20240630_lab.xml Edgar Link unprocessable
capr-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
capr-20240630x10q_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending